Rated a Top 10 free iPhone app by iMedicalApps
 
Osteoporosis
Fracture Prevention and Therapeutic Management Edition
Table of Contents  |  CME/CE Information  | Technical Requirements  | Login
  /1892/iPhoneAd/1892iPhoneAd.gif [false]



 
This CME/CE activity has expired for credit.
Click here to view our current activities in Osteoporosis.

ACCME Disclaimer
 
Chapter 1 – Overview of Osteoporosis

Contributing Editor
E. Michael Lewiecki E. Michael Lewiecki, MD, FACP, FACE
Director
New Mexico Clinical Research & Osteoporosis Center
Clinical Assistant Professor
University of New Mexico School of Medicine
Albuquerque, New Mexico
top

Activity Goal

The goal of this CME/CE activity is to address gaps in competence and practice performance by:

  • Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
  • Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
  • Providing updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, treatment regimen requirements for compliance, and their role in providing fracture prevention/reduction



Target Audience
This activity is designed for primary care physicians, including internists, family practitioners, gynecologists, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.

Learning Objectives
•   Assess the epidemiology of osteoporosis and its associated disease burden to improve screening and diagnosis of osteoporosis in at-risk individuals and those who have already experienced a fragility fracture.
•   Evaluate the bone remodeling process to determine the role of therapy in addressing the imbalance between bone resorption and formation in individuals with bone loss and osteoporosis.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.



CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

This activity is approved for 1.14 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.


top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

E. Michael Lewiecki, MD, FACP, FACE, has received grant/research support from Amgen Inc., Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; and is on the board of directors of the International Society for Clinical Densitometry.


PLANNING COMMITTEE

Jeffrey P. Levine, MD, MPH, is on the speakers bureau of Merck & Co, Inc and Procter & Gamble; on the advisory board of Amgen Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and Wyeth Pharmaceuticals. Dr. Levine will be referencing unlabeled/unapproved uses of drugs or products in his activities.

Marjorie M. Luckey, MD, is on the speakers bureau for Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis; has received consulting fees from Amgen, Inc and Novartis Pharmaceuticals Corporation.

Ethel S. Siris, MD, is on the speakers bureau for Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis; has received consulting fees from Amgen, Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis.

Gloria A. Bachmann, MD, is a consultant for and has received grant/research support from Astellas Pharma Inc, Bayer Group, Bionovo Inc, Boehringer-Ingelheim GmbH, Boston Scientific Corporation, Covance Inc, Duramed Pharmaceuticals, Inc, Femme Pharma Inc, Glaxo Smith Kline, Inc, Hoffmann-La Roche Inc, Hormos Medical, Johnson and Johnson Services, Inc, Merck and Company, Inc, Novartis Pharmaceuticals Corporation, Novo Nordisk, Inc, Procter & Gamble, Inc, QuatRx Pharmaceuticals Co., Wyeth Pharmaceuticals Inc, and Xanodyne Pharmaceuticals, Inc.

Cheryl L. Lambing, MD, is on the advisory board of Amgen Inc.

E. Michael Lewiecki, MD, FACP, FACE, has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; is on the board of directors of International Society for Clinical Densitometry.

Nancy J. Nordenson, MT (ASCP), MFA has disclosed no significant relationships.


Off-Label Drug Statement: This activity contains no discussion of unlabeled/unapproved drug uses.

Peer Reviewer has disclosed no significant relationships.

Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top 1892.01


Launch Activity

 
Projects In Knowledge®

Initial development was funded by a grant from Amgen.



Release Date: May 29, 2009.

Termination Date: December 31, 2011.

Estimated time for completion of this activity:
CME: 2.00 hours
CNE: 1.14 hours

CME/CE Instructions
To obtain CME/CE credit for this activity:
  1. Read the chapter carefully.
  2. Complete/submit the posttest and evaluation.
  3. Instantly access and print out your certificate.

There is no fee for this activity.

For questions about content or obtaining CME credit, please contact us.































 
 




ABOUT US  |  CONTACT US  |  CONTRACT  |  DIRECTIONS  |  PRIVACY POLICY  |  RESOURCES
Copyright © 1997-2017, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE and LIVING MEDICAL ETEXTBOOK are registered trademarks of Projects In Knowledge, Inc.
PROJECTS IN KNOWLEDGE • 290 W. Mt. Pleasant Avenue, Suite 2350 • Livingston, New Jersey 07039 (973) 890-8988


stringfalse